Protalix BioTherapeutics, Inc.: Form 10-K for the period ended Dec 31, 2018
Filed with the SEC on Mar 18, 2019 and accepted by EDGAR at Mar 18, 2019, 09:02 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2018-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Cost of revenue | 12 months2018-01-01 to 2018-12-31 | $9.3m | us-gaap:CostOfRevenue |
| Research and development | 12 months2018-01-01 to 2018-12-31 | $35.5m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 12 months2018-01-01 to 2018-12-31 | $10.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 12 months2018-01-01 to 2018-12-31 | −$19.3m | us-gaap:OperatingIncomeLoss |
| Net income | 12 months2018-01-01 to 2018-12-31 | −$26.5m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2018-01-01 to 2018-12-31 | −$0.18 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 12 months2018-01-01 to 2018-12-31 | −$7.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2018-01-01 to 2018-12-31 | $686.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2018-12-31 | $37.8m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2018-12-31 | $53.0m | us-gaap:AssetsCurrent |
| Total assets | At period end2018-12-31 | $61.1m | us-gaap:Assets |
| Current liabilities | At period end2018-12-31 | $25.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2018-12-31 | $114.0m | us-gaap:Liabilities |
| Shareholders' equity | At period end2018-12-31 | −$52.9m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001144204-19-014464. Last ingested by Listed: Nov 10, 2026, 16:48 ET. Listed shows no prices and gives no investment advice.